Keywords
How to Cite
Abstract
A separate group of patients who underwent radical prostatectomy are patients with isolated recurrence of cancer in lymph nodes limited by regional and/or retroperitoneal lymph nodes. As one method of treatment of this patient group it could be applied lymphadenectomy by open or laparoscopic (robot-assisted) approach. The analysis of literature references indicates an increase of overall survival in this group of patients after lymphadenectomy. Imaging techniques such as multiparametric magnetic resonance imaging and positron emission tomography allow more accurately identifying lymph nodes damage in patients with biochemical recurrence of prostate cancer after radical prostatectomy.References
Abdollah F., Briganti A., Montorsi F. et al. Contemporary Role of Salvage Lymphadenectomy in Patients with Recurrence Following Radical Prostatectomy // Europ. Urol. - 2015. - № 67. - Vol. 5. - P. 839-849.
Castellucci P., Fuccio C., Rubello D. Is there a role for (1) (1)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase №1.5 ng/ml? // Eur J Nucl Med Mol Imaging. - 2011. - № 38. - P. 55-63.
Ceci F., Castellucci P., Mamede M. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy // Eur J Nucl Med Mol Imaging. - 2013. - № 40. - P. 149-155.
Coelho R.F., Palmer K.J., Moniz R. et al. Early Complication Rates in a Single-Surgeon Series of 2500 Ro-botic-Assisted Radical Prostatectomies: Report Applying a Standardized Grading System // Eur Urol. - 2010. - Vol. 57. - P. 945-952.
DeJong, J. Pruim, P. Elsinga et al. C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer // Eur Urol. - 2003. - Vol. 44. - P. 32-39.
Giovacchini G., Picchio M., Briganti A. [11C] Choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging // J Urol. - 2010. - Vol. 184. - P. 938-943.
Giovacchini G., Picchio M., Coradeschi E. Predictive factors of [(11)C] choline PET/CT in patients with biochemical failure after radical prostatectomy // Eur J Nucl Med Mol Imaging. - 2010. - Vol. 37. - P. 301-309.
Giovacchini G., Picchio M., Scattoni V. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy // Eur J Nucl Med Mol Imaging. - 2010. - Vol. 37. - P. 1106-1116
Giovacchini G., Picchio M., Gracia-Parra R. [11C] Choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy // J Nucl Med. - 2014. - Vol. 55. - P. 233-241.
Harisinghani M.G., Barentsz J., Hahn P.F. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer // New Engl J Med. - 2003. - Vol. 348. - P. 2491-2499.
Heesakkers R.A., Hovels A.M., Jager G.J. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study // Lancet Oncol. - 2008. - Vol. 9. - P. 850-856.
Husarik D.B., Miralbell R., Dubs M. Evaluation of [(18) F]-choline PET/CT for staging and restaging of prostate cancer // Eur J Nucl Med Mol Imaging. - 2008. - Vol.
- P. 253-263. Jilg C.A., Rischke H.C., Reske S.N. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer // J Urol. - 2012. - Vol. - 188. - P. 2190-2197.
Kitajima K., Murphy R.C., Nathan M.A. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil // J Nucl Med. - 2014. - Vol. 55. - P. 223-232.
Krause B.J., Souvatzoglou M., Tuncel M. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer // Eur J Nucl Med Mol Imaging. - 2008. - Vol. 35. - P. 18-23.
Lecouvet F.E., Mouedden J. El, Collette L. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? // Eur Urol. - 2012. - Vol. 62. - P. 68-75.
Mamede M., Ceci F., Castellucci P. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level №0.5 ng/ml // Clin Nucl Med. - 2013. - Vol. 38. - P. 342-345.
Marzola M.C., Chondrogiannis S., Ferretti A. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution // Clin Nucl Med. - 2013. - Vol. 38. - P. 26-32.
Mottet, N. Prostate cancer: guidelines / N. Mottet, PJ. Bastian, J. Bellmunt, R.C.N. van den Bergh, M. Bolla, N.J. van Casteren, P. Cornford, S. Joniau, M.D. Mason, V. Matveev, T.H. van der Kwast, H. van der Poel, O. Rouvi re, T. Wiegel. - Netherlands: European Association of Urology, 2016. - 128 рp.
Panebianco V., Sciarra A., Lisi D. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP) // Eur J Radiol. - 2012. - Vol. 81. - P. 700-708.
Picchio M., Messa C., Landoni C. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography // J Urol. - 2003. - Vol. 169. - P. 1337-1340.
Richter J.A., Rodriguez M., Rioja J. Dual tracer 11C-cho-line and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment // Mol Imaging Biol. - 2010. - Vol. 12. - P. 210-217.
Rigatti P., Suardi N., Briganti A. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography // Eur Urol. - 2011. - Vol. 60. - P. 935-943.
Rinnab L., Mottaghy F.M., Simon J. [11C]Choline PET/ CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: preliminary results of a prospective study // Urol Int. - 2008. - Vol. 81. - P. 191-197.
Schilling D., Schlemmer H.P., Wagner PH. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer // BJU Int. - 2008. - Vol. 102. - P. 446-451.
Suardi N., Porter C.R., Reuther A.M. A nomogram predicting long-term biochemical recurrence after radical prostatectomy // Cancer. - 2008. - Vol. 112. - P. 12541263.
Suardi N., Karnes J., Joniau S., Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases // J Urol. - 2013. - Vol. 189. - P. 317-318.
Suardi N., Gandaglia G., Gallina A. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years // Eur Urol. - 2015. - Vol. 67. - P. 299-309.
Tilki D., Reich O., Graser A. 18F-Fluoroethylcholine PET/ CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent // Eur Urol. - 2013. - Vol. 63. - P. 792-796.
Wang L., Hricak H., Kattan M.W. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer // AJR Am J Roentgenol. - 2006. - Vol. 186. - P. 743-748.
Winter J., Uphoff R.P., Henke F. Wawroschek. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy // Urol Int. - 2010. - Vol. 84. - P. 418-423.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017